Nasdaq
$17.42▲ 2.47%vs prev close
🔒 Quotes & buy pressure are MAX onlySee plans
Market cap $449.1MShares out 25.8M sh
Chart
Filings & news by date
Hover (PC) or tap (mobile) a candle to see that day only
Filings
10- 9.17After-hours26.09.18 05:158-KKey event#●●●#●●●
Faeth Therapeutics, Inc.
Faeth Therapeutics expanded its Board of Directors from five to six members, appointing co-founder Dr. Karen Vousden as a Class II director and member of the Compensation Committee, effective September 11, 2026. Dr. Vousden will serve until the 2029 annual meeting and has been granted an option to purchase 25,000 shares of common stock under the company's 2026 Equity Incentive Plan.…more
$17.42+2.47%vs prev closeDetected5m · 30m · 60m · Next dayPLUSView filingShare
- 9.15After-hours26.09.16 05:584Ownership
Faeth Therapeutics, Inc.
Insider Karen H. Vousden of Faeth Therapeutics, Inc. reported changes in beneficial ownership of securities as of September 11, 2026. This filing serves as a Form 4 statement regarding the insider's equity holdings.…more
$17.42+2.47%vs prev closeView filingShare - 9.15After-hours26.09.16 05:573Ownership
Faeth Therapeutics, Inc.
Faeth Therapeutics, Inc. has filed a Power of Attorney authorizing Christopher Gerry and Josiah Craver to act as attorneys-in-fact for the execution and filing of SEC Forms 3, 4, and 5. This document formalizes the delegation of reporting obligations for Karen H. Vousden in her capacity as an officer, director, or beneficial owner.…more
$17.42+2.47%vs prev closeView filingShare
9 more filings
Sign up free to unlock the full feed and real-time filing & news alerts.
- ✓Free — no card required
- ✓Full real-time filing & news feed
- ✓Daily Today Report
News
GlobeNewswireNo news collected yet. New articles will appear here.